Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?

Executive Summary

Steroid treatment like Emflaza is considered standard of care and availability of other products may make payer discussions difficult.

You may also be interested in...



PTC Eyes Transition From Capital-Raising To Money-Making Company

With $1.1bn in cash plus revenue from its existing commercial products and royalties from Roche’s sales of newly approved Evrysdi to invest in R&D, PTC Therapeutics may achieve profitability in 2023.

UnitedHealth 2018 Formulary Updates Broaden Exclusions, Deter Copay Coupons

Insurer will begin excluding drugs when there are less expensive and clinically equivalent alternatives available and eliminate manufacturer coupons from the calculation of deductibles and out-of-pocket limits.

Once More Unto The Breach: PTC's Duchenne Drug Translarna Gets Advisory Cmte.

US FDA's Peripheral and Central Nervous System Drugs Advisory Committee to consider application, which PTC Therapeutics filed over protest.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC098217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel